At Investor Conferences

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px
Financing › Details

Domain Therapeutics–SEVERAL: credit, 202001 debt financing €6m fomr Bpifrance + BPALC + CIC + CEGEE

 

Period Period 2020-01-13
Organisations Money taker Domain Therapeutics S.A.
  Group Domain Therapeutics (Group)
  Money source SEVERAL
Products Product BioSensAll™ technology
  Product 2 banking
     

Domain Therapeutics S.A.. (1/13/20). "Press Release: Domain Therapeutics Secures €6 Million ($6.7M) Debt Financing". Strasbourg.

GPCR company will expand proprietary portfolio and prepare next financing round


Domain Therapeutics, a biopharmaceutical company specialized in the discovery and development of new drug candidates targeting G Protein-Coupled Receptors (GPCR) in neurology, oncology and rare diseases, announces it has closed a €6 million ($6.7M) debt financing to expand its proprietary drug portfolio and prepare the next round of financing.

After raising €3.5 million ($3.9M) in 2019 from an existing shareholder, Seventure Partners, Domain Therapeutics will use this additional financing to accelerate the development of its valuable portfolio. The French Public Investment Bank (Bpifance), Banque Populaire Alsace Lorraine Champagne (BPALC), Credit Industriel et Commercial (CIC) and Caisse d’Epargne Grand Est Europe (CEGEE) have participated in this non-dilutive financing as a strategic step towards a significant fund raising in 2020 aimed at supporting the development of its most advanced assets.

“This transaction shows the confidence of the banks in Domain Therapeutics and its business model and recognizes our ability to syndicate financial partners around our business objectives,” said Pascal Neuville, CEO, Domain Therapeutics. “This loan is part of our stepwise strategy leading to a series C in order to speed up our business activities.”

Domain will launch multiple programs, on valuable GPCR targets, aimed at reinforcing its portfolio of first-in-class drug candidates and at generating multipletarget collaboration opportunities with Pharma partners.


About Domain Therapeutics

Domain Therapeutics is a biopharmaceutical company dedicated to the discovery and early development of new drug candidates targeting transmembrane receptors, in particular, G Protein-Coupled Receptors (GPCRs), one of the most important classes of drug targets. Domain identifies and develops candidates (allosteric modulators and biased ligands) through its innovative approach and technologies. Domain has three revenue-generating pillars within its innovative business model: 1) collaboration with pharma companies for the discovery of new molecules 2) out-licensing of its bioSensAll™ technology and 3) creation of asset-centric vehicles for the development of its internal pipeline of preclinical candidates for central nervous system disorders, cancer and rare diseases. These asset-centric companies attract investment for focused development and exit is through a trade sale at an appropriate inflection point. www.domaintherapeutics.com


Media and analysts contacts

Andrew Lloyd & Associates
Jo Reeder / Juliette Schmitt Dos Santos
jo@ala.com / juliette@ala.com
Tel: +44 1273 675 10
@ALA_Group

   
Record changed: 2020-01-22

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 650x65px

More documents for Domain Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px




» top